Adopting an alternative structure for clinical trials in immunotherapy.

abstract：:This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

journal_title：Expert review of anticancer therapy

authors： Singh I,Hemal AK

更新日期：2010-05-01 00:00:00

abstract：:The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

journal_title：Expert review of anticancer therapy

authors： Shen P,Stewart JH,Levine EA

更新日期：2008-11-01 00:00:00

abstract：:Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

journal_title：Expert review of anticancer therapy

authors： Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

更新日期：2014-01-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：:Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

journal_title：Expert review of anticancer therapy

authors： Braun MS,Quirke P,Seymour MT

更新日期：2007-04-01 00:00:00

abstract：:Despite its increasing incidence over the last 30 years, the mortality rate of papillary thyroid cancer (PTC) has decreased significantly. Nevertheless, a minority of patients still present with an aggressive form of PTC that can lead to death, even after a prolonged period of survival. Many classifications exist that...

journal_title：Expert review of anticancer therapy

authors： Miccoli P,Miccoli M,Antonelli A,Minuto MN

更新日期：2009-09-01 00:00:00

abstract：INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

journal_title：Expert review of anticancer therapy

authors： Feld J,Belasen A,Navada SC

更新日期：2020-06-01 00:00:00

abstract：:More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

journal_title：Expert review of anticancer therapy

authors： Amiel GE,Lerner SP

更新日期：2006-02-01 00:00:00

abstract：:With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

journal_title：Expert review of anticancer therapy

authors： Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

更新日期：2010-09-01 00:00:00

abstract：:With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

journal_title：Expert review of anticancer therapy

authors： Dixon JM

更新日期：2002-06-01 00:00:00

abstract：:The treatment of renal cell carcinoma is rapidly changing as a result of recent evidence concerning the efficacy of biological drugs, antiangiogenetic agents and signal-transduction inhibitors. This paper will provide a critical overview of the use of immunotherapy in renal cell carcinoma and review the available data...

journal_title：Expert review of anticancer therapy

authors： Passalacqua R,Buti S,Tomasello G,Longarini R,Brighenti M,Dalla Chiesa M

更新日期：2006-10-01 00:00:00

abstract：:miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...

journal_title：Expert review of anticancer therapy

authors： Jiang C,Hu X,Alattar M,Zhao H

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

journal_title：Expert review of anticancer therapy

authors： Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

更新日期：2018-10-01 00:00:00

abstract：:Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed ...

journal_title：Expert review of anticancer therapy

authors： De Felice F,Giudice E,Bolomini G,Distefano MG,Scambia G,Fagotti A,Marchetti C

更新日期：2020-11-26 00:00:00

abstract：:Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifyin...

journal_title：Expert review of anticancer therapy

authors： Viale G,Morganti S,Ferraro E,Zagami P,Marra A,Curigliano G

更新日期：2019-09-01 00:00:00

abstract：:Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...

journal_title：Expert review of anticancer therapy

authors： Johnson SA

更新日期：2006-03-01 00:00:00

abstract：INTRODUCTION:The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinica...

journal_title：Expert review of anticancer therapy

authors： Skafida E,Kokkali S,Nikolaou M,Digklia A

更新日期：2017-06-01 00:00:00

abstract：:Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

journal_title：Expert review of anticancer therapy

authors： Kim KB,Khuri FR,Shin DM

更新日期：2001-06-01 00:00:00

abstract：:Squamous cell carcinoma of the vulva is a rare disease, accounting for approximately 5% of cancers of the female genital tract. Standard therapy for early-stage vulvar cancer mainly comprises of surgery of the vulva and groins. In locally advanced or metastatic vulvar cancer, neoadjuvant or definitive chemoradiation i...

journal_title：Expert review of anticancer therapy

authors： Mahner S,Prieske K,Grimm D,Trillsch F,Prieske S,von Amsberg G,Petersen C,Mueller V,Jaenicke F,Woelber L

更新日期：2015-06-01 00:00:00

abstract：:Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

journal_title：Expert review of anticancer therapy

authors： Warsame R,Grothey A

更新日期：2012-10-01 00:00:00

abstract：:Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleo...

journal_title：Expert review of anticancer therapy

authors： Robak T

更新日期：2008-07-01 00:00:00

abstract：:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

journal_title：Expert review of anticancer therapy

authors： Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

更新日期：2019-06-01 00:00:00

abstract：:Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

journal_title：Expert review of anticancer therapy

authors： Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

更新日期：2016-05-01 00:00:00

abstract：:Regional lymph node irradiation is usually indicated in patients with positive node breast cancer. However, there are some controversies regarding the clinical benefits of adding regional nodal irradiation to whole-breast or thoracic-wall irradiation after breast surgery especially for patients with 1 to 3 positive ax...

journal_title：Expert review of anticancer therapy

authors： Marta GN,de Moraes FY

更新日期：2015-01-01 00:00:00

abstract：:B cells play an important role in the pathogenesis of certain lymphomas and leukemias, as well as many autoimmune diseases. Antagonistic B-cell antibodies are thus gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of...

journal_title：Expert review of anticancer therapy

authors： Goldenberg DM

更新日期：2006-10-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is an effective treatment for patients with relapsed or refractory Hodgkin lymphoma. Treatment outcome is better among patients who demonstrate sensitivity to salvage chemotherapy. Approximately half of the patients undergoing autologous stem cell transplantation will be cured a...

journal_title：Expert review of anticancer therapy

authors： Murphy F,Sirohi B,Cunningham D

更新日期：2007-03-01 00:00:00

abstract：:Bladder cancer is rare in patients below the age of 50 years, and most patients are in their 60s and 70s. Radical cystectomy is the preferred approach for patients with localized disease in most European countries and the USA, and evidence is growing in favor of neoadjuvant, platinum-based chemotherapy for patients at...

journal_title：Expert review of anticancer therapy

authors： Basso U,Bassi P,Sava T,Monfardini S

更新日期：2004-12-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：:A major issue with current cancer therapy is how to ensure the maximum benefit with minimum toxicity for individual patients. With the progress of the human genome project have come high-throughput technologies for the analysis of DNA, gene expression or tumor protein in an efficient and quantitative manner. This revi...

journal_title：Expert review of anticancer therapy

authors： McLeod HL

更新日期：2002-02-01 00:00:00

abstract：:Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

journal_title：Expert review of anticancer therapy

authors： Balk C,Witjes JA

更新日期：2004-08-01 00:00:00